Q-omics provides the consensus-scored C10orf99 profile across patient tissues and cancer cell-line models. C10orf99 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, C10orf99 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, C10orf99 RNA expression shows 12,305 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight LUAD, KIRC, and HNSC as cancer lineages where C10orf99 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C10orf99 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C10orf99 survival associations across molecular data types. C10orf99 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C10orf99 RNA expression–survival associations across cancer types. High C10orf99 expression shows unfavorable associations in LUAD, PAAD, CHOL and KIRP, but favorable associations in LUSC and THCA. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for C10orf99 RNA expression.
This table summarizes C10orf99 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for C10orf99. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C10orf99 shows lower tumor expression in COAD and KICH and higher tumor expression in KIRC, KIRP, LUSC and UCEC. The KIRC box plot shows higher C10orf99 RNA expression in tumor versus normal tissue (log2 FC = +4.596, t-test p < 0.001).
This table shows molecular features associated with C10orf99 in patient tissues and cancer cell lines. In patient samples, C10orf99 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, C10orf99 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_NSCLC_LUAD.
